Fresh concerns have emerged over the circulation of suspected counterfeit anti-malaria medication in parts of Nigeria following viral warnings shared across social media platforms about fake versions of the popular Lonart-DS malaria drug allegedly being sold in pharmacies and medicine stores.
The alert, accompanied by comparison images of two different blister packs, claims that the original medication comes in a yellow blister pack, while the suspected counterfeit version is packaged in a white blister card. The message has triggered widespread reactions among consumers worried about the growing threat of fake pharmaceutical products within the country’s healthcare market.
Brandspur Health News gathered that public health advocates are urging Nigerians to remain cautious when purchasing anti-malaria drugs and other medications, especially from unverified outlets. Consumers have also been advised to inspect drug packaging carefully, check for NAFDAC registration details, verify scratch codes where available, and purchase medicines only from licensed pharmacies and accredited medical stores.
Healthcare professionals warn that counterfeit anti-malaria drugs pose serious risks to patients, including treatment failure, worsening infections and the potential development of drug-resistant malaria strains. Medical experts note that fake medicines often contain incorrect dosages, harmful substances or inactive ingredients that may endanger public health.
Although regulatory authorities are yet to officially confirm the authenticity of the viral claims surrounding the product comparison, stakeholders within Nigeria’s pharmaceutical sector say the circulation of counterfeit drugs remains a major concern requiring stronger enforcement, improved consumer awareness and tighter supply chain monitoring.
The latest warning comes amid ongoing efforts by health regulators and pharmaceutical agencies to combat fake and substandard medicines across Nigeria’s healthcare system, particularly within the anti-malaria market where demand for treatment remains consistently high due to the country’s malaria burden.
